This is supported by a previous study demonstrating that the silencing of a new RNP complex composed of RBPs (HNRNPK) or FXR1 augmented primary tumor growth, while the simultaneous silencing of HNRNPK and FXR2 or the triple silencing of HNRNPK, FXR1, and FXR2 markedly reduced primary tumor growth, suggesting that the co-expression of HNRNPK and FXR2 is essential for in vivo primary tumor growth (Figure 4) [23]. The gene discussed is FXR1; the disease is neoplasm.